ClinicalTrials.gg

Program

ravulizumab

Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Furthest: phase 4, since Mar 23, 202035 company-led studies, 9 open or runningNext primary completion: Jun 25, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca349 open or runningphase 4since Mar 23, 2020Nov 2, 2015Jun 25, 2027phase 4 · NCT07308574
Regeneron Pharmaceuticals10 open or runningphase 3since Nov 12, 2021Nov 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Nov 2, 2015.

  1. Nov 12, 2021Regeneron Pharmaceuticals's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05131204 · 3 enrolled · United States
  2. Mar 11, 20224 phase 1 studies in HealthyAstraZeneca · NCT05288829, NCT05288816, NCT05288673 and 1 more
  3. Apr 20, 2022Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT05346354 · 12 enrolled · United States, Canada, France and more
  4. May 25, 2022Phase 1 study in HealthyAstraZeneca · NCT05396742 · 49 enrolled · United Kingdom
  5. Dec 1, 2022Phase 3 study in Myasthenia GravisAstraZeneca · NCT05644561 · 12 enrolled · United States, Italy, Japan and more
  6. Feb 16, 2023Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT05746559 · 555 enrolled · United States, Argentina, Australia and more
  7. Feb 26, 2024Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT06291376 · 584 enrolled · United States, Argentina, Australia and more
  8. Aug 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalAstraZeneca · NCT06578949 · 18 enrolled · China
  9. Feb 10, 2025Phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798 · 450 planned · United States, Argentina, Australia and more
  10. Jun 9, 2025Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT07024563 · 36 planned · United States, China, Italy and more
  11. Oct 3, 2025Phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838 · 75 planned · United States, Germany, Italy and more
  12. Dec 17, 2025Phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574 · 20 planned · Japan
  13. Apr 23, 2026Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT07557420 · 19 planned · China
  14. May 13, 2026Phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784 · 20 planned · China

Ahead

  1. Jun 25, 2027Primary completion: phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574
  2. Aug 24, 2027Primary completion: phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784
  3. Aug 27, 2027Primary completion: phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838
  4. Nov 30, 2027Primary completion: phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07596784Myasthenia Gravis · China3RecruitingAstraZenecaAug 24, 202720
NCT07557420Neuromyelitis Optica · China3RecruitingAstraZenecaSep 19, 202819
NCT07308574Atypical Hemolytic Uremic Syndrome · Japan4RecruitingAstraZenecaJun 25, 202720
NCT07221838Myasthenia Gravis · United States, Germany, Italy and more4RecruitingAstraZenecaAug 27, 202775
NCT07024563Glomerulonephritis, IGA · United States, China, Italy and more3RecruitingAstraZenecaNov 29, 202836
NCT06830798Delayed Graft Function · United States, Argentina, Australia and more3RecruitingAstraZenecaNov 30, 2027450
NCT06578949Hemoglobinuria, Paroxysmal · China3CompletedAstraZenecaMay 15, 202518
NCT06291376Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaJan 5, 2026584
NCT05746559Renal Insufficiency, Chronic · United States, Argentina, Australia and more3TerminatedAstraZenecaOct 7, 2025555
NCT05644561Myasthenia Gravis · United States, Italy, Japan and more3Active, not recruitingAstraZenecaJul 15, 202612
NCT05396742Healthy · United Kingdom1CompletedAstraZenecaMay 21, 201949
NCT05346354Neuromyelitis Optica · United States, Canada, France and more3Active, not recruitingAstraZenecaJun 22, 202612
NCT05288829Healthy · United Kingdom1CompletedAstraZenecaJul 18, 201742
NCT05288816Healthy · United Kingdom1CompletedAstraZenecaJul 5, 201716
NCT05288673Healthy · United Kingdom1CompletedAstraZenecaSep 1, 201616
NCT05288660Healthy · Canada1CompletedAstraZenecaMar 13, 201514
NCT05131204Hemoglobinuria, Paroxysmal · United States3TerminatedRegeneron PharmaceuticalsJul 12, 20233
NCT04999020Dermatomyositis · United States, Australia, Brazil and more3TerminatedAstraZenecaOct 26, 202338
NCT04743804Thrombotic Microangiopathies · United States, Belgium, Brazil and more3TerminatedAstraZenecaDec 22, 202216
NCT04564339Lupus Nephritis · United States, Australia, Canada and more2TerminatedAstraZenecaMar 26, 2025123
NCT04557735Thrombotic Microangiopathies · United States, Israel, Italy and more3CompletedAstraZenecaNov 26, 202441
NCT04543591Thrombotic Microangiopathies · United States, Australia, Belgium and more3CompletedAstraZenecaSep 19, 2025148
NCT04369469Acute Lung Injury · United States, France, Japan and more3TerminatedAstraZenecaFeb 8, 2021202
NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom4CompletedAstraZenecaDec 20, 202218
NCT04248465Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more3TerminatedAstraZenecaOct 17, 2021382
NCT04201262Neuromyelitis Optica · United States, Australia, Austria and more3CompletedAstraZenecaMar 15, 202258
NCT03920293Myasthenia Gravis · United States, Austria, Canada and more3CompletedAstraZenecaMay 11, 2021175
NCT03748823Hemoglobinuria, Paroxysmal · United States, Australia, Austria and more3CompletedAstraZenecaFeb 2, 2021139
NCT03406507Hemoglobinuria, Paroxysmal · United States, France, Netherlands and more3CompletedAstraZenecaMar 25, 202013
NCT03131219Atypical Hemolytic Uremic Syndrome · United States, Belgium, Germany and more3CompletedAstraZenecaDec 20, 202234
NCT03056040Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more3CompletedAstraZenecaFeb 21, 2022202
NCT02949128Atypical Hemolytic Uremic Syndrome · United States, Australia, Austria and more3CompletedAstraZenecaJan 24, 202358
NCT02946463Hemoglobinuria, Paroxysmal · United States, Argentina, Australia and more3CompletedAstraZenecaFeb 28, 2023272
NCT02605993Hemoglobinuria, Paroxysmal · Canada, France, Germany and more2CompletedAstraZenecaFeb 23, 201726
NCT02598583Hemoglobinuria, Paroxysmal · Australia, Korea, Republic of2CompletedAstraZenecaJul 14, 201613

How it is read

Names in the registry

  • “Ravulizumab”, 30 entries
  • “ALXN1210”, 4 entries
  • “ALXN1210 SC”, 1 entry
  • “ALXN1210 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.